Nosa Med AB Net Assets
Nosa Med AB net assets. Based on the latest financial reports, Nosa Med AB (NOSA) has net assets worth Skr41.06 Million SEK (≈ $4.42 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr64.71 Million ≈ $6.96 Million USD) and total liabilities (Skr23.65 Million ≈ $2.55 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NOSA year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr41.06 Million |
| % of Total Assets | 63.45% |
| Annual Growth Rate | -14.49% |
| 5-Year Change | 5.01% |
| 10-Year Change | N/A |
| Growth Volatility | 61.86 |
Net Assets of Nosa Med AB (2016–2025)
Net assets of Nosa Med AB from 2016 to 2025. This chart illustrates how Nosa Med AB's net assets have evolved over time, based on quarterly financial data. See how leveraged is Nosa Med AB's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Nosa Med AB (2016–2025)
The table below shows the annual net assets of Nosa Med AB from 2016 to 2025. For live market cap and overall valuation, see market cap of Nosa Med AB.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr41.06 Million ≈ $4.42 Million |
+148.02% |
| 2024-12-31 | Skr16.56 Million ≈ $1.78 Million |
-38.11% |
| 2023-12-31 | Skr26.75 Million ≈ $2.88 Million |
+45.90% |
| 2022-12-31 | Skr18.34 Million ≈ $1.97 Million |
-53.11% |
| 2021-12-31 | Skr39.10 Million ≈ $4.21 Million |
-61.53% |
| 2020-12-31 | Skr101.64 Million ≈ $10.94 Million |
-45.89% |
| 2019-12-31 | Skr187.85 Million ≈ $20.22 Million |
-6.26% |
| 2018-12-31 | Skr200.39 Million ≈ $21.56 Million |
+4.25% |
| 2017-12-31 | Skr192.22 Million ≈ $20.69 Million |
+14.38% |
| 2016-12-31 | Skr168.06 Million ≈ $18.09 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nosa Med AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8817600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Nosa Med AB Net Assets Breakdown (December 2025)
Nosa Med AB net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr13.01 Million | 31.68% |
| Other Comprehensive Income | Skr-126.00K | -0.31% |
| Other Components | Skr139.72 Million | 340.27% |
| Total Equity | Skr41.06 Million | 100.00% |
Nosa Med AB Competitors by Market Cap
The table below lists competitors of Nosa Med AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
QPR Software Oyj
HE:QPR1V
|
$11.26 Million |
|
Ancora Indonesia Resources Tbk
JK:OKAS
|
$11.27 Million |
|
Smart Logistics Global Limited Ordinary Shares
NASDAQ:SLGB
|
$11.27 Million |
|
Advanced Packaging Tech (Malaysia)
KLSE:9148
|
$11.27 Million |
|
Dycasa SA
BA:DYCA
|
$11.25 Million |
|
Blackwall Ltd
AU:BWF
|
$11.24 Million |
|
Sirona Biochem Corp
V:SBM
|
$11.23 Million |
|
Thai Wire Products Public Company Limited
BK:TWP
|
$11.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nosa Med AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 16,556,000 to 41,063,000, a change of 24,507,000 (148.0%).
- Net loss of 8,041,000 reduced equity.
- New share issuances of 32,255,000 increased equity.
- Other comprehensive income decreased equity by 126,000.
- Other factors increased equity by 419,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-8.04 Million | -19.58% |
| Share Issuances | Skr32.26 Million | +78.55% |
| Other Comprehensive Income | Skr-126.00K | -0.31% |
| Other Changes | Skr419.00K | +1.02% |
| Total Change | Skr- | 148.02% |
Book Value vs Market Value Analysis
This analysis compares Nosa Med AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.32x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.04x to 2.32x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Skr11.22 | Skr0.40 | x |
| 2017-12-31 | Skr11.03 | Skr0.40 | x |
| 2018-12-31 | Skr9.98 | Skr0.40 | x |
| 2019-12-31 | Skr7.59 | Skr0.40 | x |
| 2020-12-31 | Skr3.20 | Skr0.40 | x |
| 2021-12-31 | Skr0.81 | Skr0.40 | x |
| 2022-12-31 | Skr0.11 | Skr0.40 | x |
| 2023-12-31 | Skr0.17 | Skr0.40 | x |
| 2024-12-31 | Skr0.08 | Skr0.40 | x |
| 2025-12-31 | Skr0.17 | Skr0.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nosa Med AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.63%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.58x
- Recent ROE (-19.58%) is above the historical average (-98.02%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -10.89% | 0.00% | 0.00x | 1.02x | Skr-35.11 Million |
| 2017 | -12.95% | -10037.90% | 0.00x | 1.04x | Skr-44.12 Million |
| 2018 | -20.97% | -799.52% | 0.02x | 1.07x | Skr-62.05 Million |
| 2019 | -39.27% | -3810.07% | 0.01x | 1.08x | Skr-92.55 Million |
| 2020 | -225.42% | -16760.42% | 0.01x | 1.14x | Skr-239.28 Million |
| 2021 | -149.76% | -1000.43% | 0.15x | 1.03x | Skr-62.48 Million |
| 2022 | -266.00% | -260.18% | 0.32x | 3.23x | Skr-18.49 Million |
| 2023 | -174.03% | -447.94% | 0.31x | 1.24x | Skr-49.23 Million |
| 2024 | -61.36% | -63.10% | 0.78x | 1.25x | Skr-11.81 Million |
| 2025 | -19.58% | -33.63% | 0.37x | 1.58x | Skr-12.15 Million |
Industry Comparison
This section compares Nosa Med AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $471,003,634
- Average return on equity (ROE) among peers: -36.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nosa Med AB (NOSA) | Skr41.06 Million | -10.89% | 0.58x | $11.26 Million |
| Acarix A/S (ACARIX) | $75.70 Million | -87.44% | 0.07x | $23.63 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $13.21 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $417.44 Million | -6.35% | 0.62x | $53.79 Million |
| BICO Group AB (BICO) | $3.01 Billion | -0.18% | 0.82x | $174.69 Million |
| Boule Diagnostics AB (BOUL) | $269.60 Million | -82.83% | 1.19x | $3.55 Million |
| CellaVision AB (CEVI) | $815.73 Million | 17.25% | 0.24x | $490.26 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $10.83 Million | -64.40% | 0.20x | $9.27 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $35.05 Million | -30.59% | 0.38x | $82.28 Million |
| Duearity AB (DEAR) | $3.79 Million | -34.93% | 0.15x | $331.97K |
About Nosa Med AB
Nosa Plugs AB, a medical technology company, develops, manufactures, and sells intranasal breathing products in Sweden, rest of Europe, the United States, Canada, and internationally. The company offers NOSA allergy filter that filters airborne allergens, such as pollen, pet dander, dust, and mold; NOSA smell training, a smell training medical device to improve the sense of smell for individuals … Read more